share_log

中恒集团(600252.SH):控股子公司盐酸纳洛酮注射液获得药品注册证书

Guangxi Wuzhou Zhongheng Group (600252.SH): Its holding subsidiary Naloxone hydrochloride injection has obtained the pharmaceutical registration certificate.

Gelonghui Finance ·  Jun 4 05:57

On June 4th, Gelonghui reported that Guangxi Wuzhou Zhongheng Group (600252.SH) announced that its subsidiary, Chongqing Lummy Pharmaceutical Co., Ltd. (referred to as "Lummy Pharmaceutical"), has received the National Medical Products Administration's approval and issuance of a registration certificate for naloxone hydrochloride injection with a specification of 1ml:0.4mg. The naloxone hydrochloride injection was developed by the American company ADAPT Pharmaceuticals and is currently marketed in the United States and Japan, and has not yet been imported in China. Naloxone hydrochloride injection is an opioid receptor antagonist used for opioid anesthesia after surgery to counteract respiratory depression caused by opioid drugs, promote patient awakening; used for opioid drug overdose, complete or partial reversal of respiratory depression caused by opioid drugs; for rescuing acute ethanol poisoning; and for diagnosing acute opioid drug overdose.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment